Cancer Treatment Centers of America Helps to Launch New Platform that will Help the World of Oncology Be More Effective

The world of oncology is dedicated to the study, research, and treatment of cancer. Cancer is a devastating disease that has affected the lives of millions of people and their families who must fight it every day. The fight to overcome cancer can feel like an uphill battle and many people feel like their treatment options are limited. Thanks to Cancer Treatment Centers of America partnering up with NantHealth and Allscripts, together they have been able to launch a new platform called Clinical Pathways.

Clinical Pathways will help to change the standard of care patients can expect when they seek out treatment. The idea behind the newly launched platform is to provide appropriate treatment options to patients to help eliminate the potential guesswork that is often done by clinicians. The new data and research that goes on in oncology will become more widely available and easy to access, allowing oncologists to specialize the treatment options for their patients.
Cancer Treatment Centers of America takes a similar approach with their patients, believing in personalized care to ensure they have the best treatment options available to them. The heart of CTCA stems from how it was founded originally in 1988 by Richard J. Stephenson. His mother passed away from cancer, but during her time with the disease, he wasn’t satisfied with the treatment options available to her. He went on to found the first CTCA at Midwestern Regional Medical Center in Zion, Illinois.
Ever since CTCA has been founded it has slowly begun to expand, with four more hospitals opening between 2005 to 2012. The organized since then has even become the first international patient concierge and information office. CTCA opened in Lomas de Chapultepec neighborhood in Mexico City on April 20, 2015. CTCA has continued to maintain an active presence in other areas of the world too like Latin America, the Middle East, and the Caribbean.

Comments are closed.